Skip to content
Medical Health Aged Care, Mental Health

Opioid agonist treatment program prevents hundreds of suicides in NSW, study finds

National Drug & Alcohol Research Centre (NDARC), UNSW Sydney 3 mins read

Widespread access to opioid agonist treatment (OAT) can reduce the risk of suicide by 35% among people with opioid use disorder, according to a new study published in Addiction.

Researchers led by the National Drug and Alcohol Research Centre (NDARC) at UNSW Sydney said their findings suggest the OAT program in NSW averted an estimated 338 suicides between 2001 and 2020.

“Our study underscores the critical role of OAT, including methadone and buprenorphine, as life-saving medications and a key public health intervention in reducing suicide risk among people with opioid use disorder,” said Dr Thomas Santo Jr, a Postdoctoral Research Fellow at NDARC and lead author of the study.

“It also highlights the urgent need to expand access to OAT – both locally and globally – given the potential to reduce suicide-related deaths in these individuals by more than one-third.”

Global estimates for attempted suicide prevalence in people with opioid use disorder range from 20% to 50%, and around one in 12 deaths in this population are due to suicide.

OAT is widely recognised as the most effective treatment for reducing overdose deaths in people with opioid use disorder, but its role in suicide prevention has been less clear.

To address this, Dr Santo Jr’s team analysed data from nearly 47,000 individuals who received OAT in community and prison settings in NSW between 2001 and 2017. They then estimated the number of suicides prevented by the OAT program over a 20-year period.

Based on their modelling, access to OAT was estimated to have averted 338 suicides – 325 in the community and 13 in prison – between 2001 and 2020.

This corresponds to 35% of suicide deaths averted in the community and 27% in prison settings among people with opioid use disorder.

“Without an OAT program in NSW, we estimate that nearly 960 suicides could have occurred among people with opioid use disorder between 2001 and 2020. Instead, with OAT in place, 338 of these suicides were prevented, leading to a gain of 2,704 life-years—highlighting its life-saving impact,” said Dr Santo Jr.

“Specifically, our study indicates that OAT provision was linked to a prevention of 2% of all suicides that occurred in NSW during the same period—a modest impact, but still crucial to achieving the WHO and UN Sustainable Development Goal targets to cut suicide rates by one-third by 2030.

“Given its proven effectiveness in reducing suicide risk, particularly compared to many other interventions, expanding access to OAT should be a priority in broader suicide prevention strategies.”

Dr Santo Jr added that access to OAT could also reduce health inequities in NSW, as individuals experiencing homelessness, those from lower socio-economic backgrounds, and Aboriginal communities have disproportionately high rates of opioid use disorder.

“A population-level intervention like OAT can make a substantial difference in preventing suicide among marginalised communities, particularly given the structural and systemic barriers they face in accessing mental health and suicide prevention services.”

One limitation is that these findings are based on the OAT program in NSW and may not apply to all programs or communities. The high coverage rate, with nearly 90% of people with opioid use disorder having received OAT at least once, is likely a key factor in the program’s widespread impact and its effect on suicide prevention in this setting.

-ENDS-


Contact details:

NDARC media: 0401 713 850 | [email protected]

For reference: When reporting on drugs and alcohol, we encourage consultation of the Mindframe guidelines on Communicating about alcohol and other drugs’ and ‘Communicating about suicide, and the ‘Language Matters guide published by the NSW Users and AIDS Association. 

We also encourage inclusion of the following helpline information in all reporting:

People can access free and confidential advice about alcohol and other drugs by calling the National Alcohol and Other Drug Hotline on 1800 250 015.

More from this category

  • Government Federal, Mental Health
  • 17/12/2025
  • 17:05
Australians for Mental Health

Australians for Mental Health welcomes mental health spend in mid-year budget update

Australians for Mental Health welcomes mental health spend in mid-year budget update Australians for Mental Health has welcomed the federal government’s decision to fund its election commitment of more than $1 billion for mental health care. The Mid-Year Economic and Fiscal Outlook released today confirms the mental health funding boosts, which will expand services and provide a boost to the workforce. The funding includes $500 million spent on a new network for 20 Youth Specialist Care Centres, $267.3 million for 32 new and upgraded Medicare Mental Health Centres, $225.3 million for 58 new, upgraded or expanded Headspace services and $83.9…

  • Medical Health Aged Care
  • 17/12/2025
  • 13:11
GE HealthCare

GE HealthCare and Indonesia’s Ministry of Health to expand access to quality care through the provision of 300+ advanced CT scanners

300+ advanced CT scanners to be installed in public hospitals across 38 provinces by 2028, to support early diagnosis and treatment of non-communicable diseases.…

  • Contains:
  • Finance Investment, Medical Health Aged Care
  • 17/12/2025
  • 12:03
Jane Morgan Management

LTR Pharma surpasses 1,000 SPONTANĀ® prescriptions under TGA Special Access Scheme

Highlights More than 1,000 SPONTAN® prescriptions issued under the TGA Special Access Scheme Growing prescriber network with continued uptake in complex ED cases, including post-prostate cancer patients Real-world insights informing US commercial strategy ahead of ROXUS® launch in H1 CY2026 LTR Pharma Limited (ASX:LTP) (“LTR Pharma” or “the Company”) is pleased to announce that more than 1,000 SPONTAN® prescriptions have now been issued in Australia under the Therapeutic Goods Administration (TGA) Special Access Scheme (SAS Category B). SPONTAN is being prescribed for patients with unmet clinical needs, including men who have not achieved adequate benefit from traditional oral PDE5 inhibitor…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.